{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:59:39Z","timestamp":1792699179051,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.critrevonc.2020.103143","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T02:13:45Z","timestamp":1604715225000},"page":"103143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Efficacy of intravenous NEPA, a fixed NK1\/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-8319","authenticated-orcid":false,"given":"Matti","family":"Aapro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph M.","family":"Navari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Roeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2020.103143_bib0005","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0010","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103143_bib0015","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/1078155218808084","article-title":"Infusion site reactions following administration of intravenous rolapitant at an academic medical center","volume":"25","author":"Cass","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103143_bib0020","first-page":"557","article-title":"Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses","volume":"26","author":"Clark-Snow","year":"2019","journal-title":"Support. Care Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103143_bib0025","first-page":"4099","article-title":"Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting: results of a European Oncology nurse survey","volume":"27","author":"Dielesenger","year":"2019","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2020.103143_bib0030","first-page":"379","article-title":"Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens","volume":"35","author":"Fujii","year":"2015","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103143_bib0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0040","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","article-title":"Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol\u2014EASE","volume":"29","author":"Grunberg","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0045","first-page":"55","article-title":"An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy","volume":"23","author":"Hegerova","year":"2015","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2020.103143_bib0050","series-title":"Akynzeo\u00ae (netupitant and Palonosetron) Capsules and Akynzeo\u00ae for Injection (fosnetupitant and Palonosetron) [prescribing Information]","author":"Helsinn Therapeutics Inc","year":"2018"},{"key":"10.1016\/j.critrevonc.2020.103143_bib0055","series-title":"Cinvanti\u2122 (aprepitant) Injectable Emulsion, for Intravenous Use [prescribing Information]","author":"Heron Therapeutics","year":"2017"},{"issue":"22","key":"10.1016\/j.critrevonc.2020.103143_bib0060","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"Hesketh","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0065","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0070","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: American Society of Clinical Oncology Guideline Update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0075","first-page":"979","article-title":"Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial","volume":"22","author":"Hu","year":"2014","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2020.103143_bib0080","first-page":"1313","article-title":"Fosaprepitant induced phlebitis: a focus on patients receiving doxorubicin\/cyclophosphamide therapy","volume":"22","author":"Leal","year":"2014","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2020.103143_bib0085","series-title":"Emend (fosaprepitant) for Injection, for Intravenous Use [prescribing Information] Whitehouse Station","author":"Merck and Co","year":"2018"},{"key":"10.1016\/j.critrevonc.2020.103143_bib0090","series-title":"Emend (aprepitant) Capsules, for Oral Use and Emend (aprepitant) for Oral Suspension [prescribing Information]","author":"Merck & Co","year":"2017"},{"key":"10.1016\/j.critrevonc.2020.103143_bib0095","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Antiemesis. Version 2.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf [accessed May 2020]."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0100","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.2147\/OTT.S201609","article-title":"Crossover safety study of aprepitant: 2-minute injection vs 30-minute infusion in cancer patients receiving emetogenic chemotherapy","volume":"12","author":"Navari","year":"2019","journal-title":"Onco. Ther."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0105","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.2147\/OTT.S158570","article-title":"Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting","volume":"11","author":"Navari","year":"2018","journal-title":"Onco. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103143_bib0110","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1200\/JOP.19.00457","article-title":"Impact of the addition of carboplatin AUC \u2265 4 to antiemetic guidelines for triple antiemetic prophylaxis: A gap in quality of care, guideline adoption, and avoiding acute care","volume":"16","author":"Navari","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0115","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/fon-2018-0809","article-title":"HTX-019 via 2-min injection or 30-min infusion in healthy subjects","volume":"15","author":"Ottoboni","year":"2019","journal-title":"Future Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103143_bib0120","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103143_bib0125","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1470-2045(15)00035-2","article-title":"Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials","volume":"16","author":"Rapoport","year":"2015","journal-title":"Lancet"},{"issue":"3.5","key":"10.1016\/j.critrevonc.2020.103143_bib0130","article-title":"Avoidable acute care use associated with nausea and vomiting among patients receiving highly emetogenic chemotherapy or oxaliplatin","volume":"17","author":"Roeland","year":"2019","journal-title":"JNCCN"},{"issue":"suppl 5","key":"10.1016\/j.critrevonc.2020.103143_bib0135","first-page":"v119","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2013.08.049","article-title":"Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis","volume":"722","author":"Rojas","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0145","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mds541","article-title":"Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"24","author":"Saito","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0150","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7150\/jca.7706","article-title":"Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients","volume":"5","author":"Sato","year":"2014","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103143_bib0155","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","article-title":"Comparison of aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment","volume":"17","author":"Schmoll","year":"2006","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103143_bib0160","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(15)00034-0","volume":"16","author":"Schwartzberg","year":"2015","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103143_bib0165","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdy169","article-title":"Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy","volume":"29","author":"Schwartzberg","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0170","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s12325-018-0707-z","article-title":"Safety of polysorbate 80 in the oncology setting","volume":"35","author":"Schwartzberg","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0175","first-page":"1","article-title":"Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy","volume":"24","author":"Schwartzberg","year":"2019","journal-title":"The Oncol"},{"issue":"1-3","key":"10.1016\/j.critrevonc.2020.103143_bib0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2012.05.037","article-title":"Inhibition of substance P-mediated responses in NG108-115 cells by netupitant and palonosetron exhibit synergistic effects","volume":"689","author":"Stathis","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0185","series-title":"VARUBI (rolapitant) Tablets, for Oral Use [prescribing Information]","author":"TerSera Therapeutics LLC","year":"2020"},{"key":"10.1016\/j.critrevonc.2020.103143_bib0190","series-title":"Varubi\u00ae (rolapitant) injectable emulsion, for intravenous use [prescribing Information]","author":"TESARO, Inc","year":"2017"},{"key":"10.1016\/j.critrevonc.2020.103143_bib0195","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3892\/mco.2016.769","article-title":"Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: a retrospective comparison","volume":"4","author":"Tsuda","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0200","unstructured":"U.S. Food & Drug Administration. Safety alerts for human medicinal products. Healthcare provider letter. Available at https:\/\/www.fda.gov\/media\/110258\/download. Accessed November 2019."},{"key":"10.1016\/j.critrevonc.2020.103143_bib0205","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103143_bib0210","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820302791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820302791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:39:07Z","timestamp":1760902747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820302791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":42,"alternative-id":["S1040842820302791"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103143","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of intravenous NEPA, a fixed NK1\/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103143"}}